UPDATED Jun 17, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$885.01 | 2.3% | 97.7% | US$791.0b | US$855.39 | PE129.8x | E27.3% | 0.6% | Pharmaceuticals & Biotech | ||
UNH | US$489.23 | -1.2% | 6.7% | US$457.5b | US$575.77 | PE29.3x | E19.7% | 1.5% | Healthcare | ||
JNJ | US$145.95 | -0.8% | -11.1% | US$350.3b | US$171.72 | PE20.6x | S4.4% | 3.4% | Pharmaceuticals & Biotech | ||
MRK | US$127.50 | -3.0% | 16.6% | US$327.9b | US$142.68 | PE140x | E23.7% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$169.68 | -0.5% | 22.4% | US$297.7b | US$183.04 | PE50.3x | E23.3% | 3.7% | Pharmaceuticals & Biotech | ||
AZN | UK£124.28 | -1.4% | 6.7% | UK£192.7b | UK£136.65 | PE38.7x | E14.7% | 2.0% | Pharmaceuticals & Biotech | ||
TMO | US$568.00 | -2.3% | 5.7% | US$218.4b | US$629.47 | PE35.9x | E10.6% | 0.3% | Pharmaceuticals & Biotech | ||
DHR | US$254.13 | -4.0% | 5.1% | US$188.8b | US$273.31 | PE46.3x | E13.8% | 0.4% | Pharmaceuticals & Biotech | ||
ABT | US$103.45 | -3.8% | -2.6% | US$180.4b | US$125.37 | PE32.1x | E11.3% | 2.1% | Healthcare | ||
AMGN | US$303.28 | -0.5% | 32.1% | US$160.2b | US$316.44 | PE43.2x | E18.2% | 3.0% | Pharmaceuticals & Biotech | ||
PFE | US$26.98 | -3.9% | -32.7% | US$156.0b | US$31.92 | PS2.8x | E30.6% | 6.2% | Pharmaceuticals & Biotech | ||
ISRG | US$430.17 | 2.8% | 30.6% | US$151.0b | US$423.57 | PE76.8x | E11.7% | n/a | Healthcare | ||
SYK | US$344.70 | -1.0% | 17.1% | US$131.4b | US$372.50 | PE39.1x | E10.5% | 0.9% | Healthcare | ||
ELV | US$534.38 | -0.3% | 20.6% | US$124.3b | US$607.19 | PE19.9x | E12.2% | 1.2% | Healthcare | ||
VRTX | US$473.69 | -2.0% | 36.2% | US$124.1b | US$463.42 | PE30.4x | E10.4% | n/a | Pharmaceuticals & Biotech | ||
BSX | US$76.19 | -1.6% | 40.3% | US$112.9b | US$82.26 | PE63.5x | E18.2% | n/a | Healthcare | ||
REGN | US$1,045.37 | 4.4% | 33.5% | US$111.8b | US$1,051.47 | PE29.2x | E12.5% | n/a | Pharmaceuticals & Biotech | ||
MDT | US$79.95 | -3.8% | -10.3% | US$106.3b | US$94.07 | PE28.5x | E12.9% | 3.5% | Healthcare | ||
CI | US$333.90 | -1.4% | 24.2% | US$94.7b | US$392.04 | PE26.2x | E17.9% | 1.7% | Healthcare | ||
CSL | AU$288.80 | -0.07% | 1.5% | AU$139.6b | AU$308.62 | PE37.3x | E14.7% | 1.2% | Pharmaceuticals & Biotech | ||
HCA | US$335.47 | -1.7% | 15.6% | US$88.4b | US$351.29 | PE16.1x | E6.0% | 0.8% | Healthcare | ||
BMY | US$40.97 | -3.8% | -38.1% | US$83.5b | US$53.19 | PS1.8x | E44.7% | 5.9% | Pharmaceuticals & Biotech | ||
GSK | UK£16.00 | -1.3% | 18.4% | UK£65.2b | UK£20.36 | PE14.6x | E12.3% | 3.6% | Pharmaceuticals & Biotech | ||
GILD | US$64.27 | -1.5% | -18.5% | US$81.1b | US$82.70 | PE165.1x | E36.2% | 4.8% | Pharmaceuticals & Biotech |